MP41-13 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL

Thomas Powles,Daniel P. Petrylak,Se Hoon Park,Srikala S. Sridhar,Claudia Caserta,Antoine Thiery-Vuillemin,Hyo Jin Lee,Joaquim Bellmunt,Yoshiaki Yamamoto,Jeanny B. Aragon-Ching,Bo Huang,Keith A. Ching,Craig Davis,Alessandra di Pietro,Yohann Loriot,Petros Grivas

MP41-13 AVELUMAB FIRST-LINE MAINTENANCE FOR ADVANCED UROTHELIAL CARCINOMA: ANALYSIS OF CLINICAL AND GENOMIC SUBGROUPS FROM THE JAVELIN BLADDER 100 TRIAL

2021

Thomas Powles
Daniel P. Petrylak
Se Hoon Park
Srikala S. Sridhar
Claudia Caserta
Antoine Thiery-Vuillemin
Hyo Jin Lee
Joaquim Bellmunt
Yoshiaki Yamamoto
Jeanny B. Aragon-Ching
Bo Huang
Keith A. Ching
Craig Davis
Alessandra di Pietro
Yohann Loriot
Petros Grivas

INTRODUCTION AND OBJECTIVE:In the phase 3 JAVELIN Bladder 100 trial, avelumab first-line (1L) maintenance+best supportive care (BSC) significantly prolonged overall survival (OS) vs BSC alone in pa...

Keywords:

Oncology
overall survival
first line
urothelial carcinoma
Avelumab
Medicine
Javelin
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations